Informed Prostate Cancer Patient Support

  Clinical Trials & Emerging Therapies A New “AR-Degrader” Trial Opens for Advanced Prostate Cancer GSK has begun the first human study of GSK5471713, an experimental drug designed not just to block the androgen receptor but to destroy it. Here is what the trial does, why it asks for the patients it asks for, and how a man might think through whether joining makes sense. for the IPCSG Newsletter  |  Reviewed September 2026 Bottom Line Up Front A new Phase 1/2 clinical trial (identifier NCT07332455 ) is now recruiting men with metastatic castration-resistant prostate cancer (mCRPC) to test GSK5471713 , an experimental GSK drug that belongs to the emerging class of androgen-receptor (AR) degraders . Instead of merely blocking the receptor the way enzalutamide or abiraterone do, degraders aim to tag the AR protein for the cell’s own disposal system so it is broken down entirely. This is an early, first-in-human study . Its main job is to find...

IPCSG Newsletter · Research on the Horizon The JANX014 Trial A "double-masked" T-cell engager for advanced prostate cancer has entered its first human study — developed by a San Diego company and being tested close to home. Prepared for the Informed Prostate Cancer Support Group · September 2026 Bottom Line Up Front JANX014 is an experimental prostate-cancer immunotherapy now in its earliest stage of human testing (Phase 1) for men with metastatic castration-resistant prostate cancer (mCRPC) . It is a "double-masked" T-cell engager — a drug engineered to stay switched off in the bloodstream and turn on only after it reaches the tumor, an approach meant to widen the safety margin and reduce the immune-overactivation reaction (cytokine release syndrome) that has limited earlier drugs of this type. It is made by San Diego–based Janux Therapeutics , and the study is recruiting at six U.S. centers — the first of which is UC San Diego's Moore...

Scientists find a new weakness in treatment-resistant prostate cancer | ScienceDaily IPCSG  Informed Prostate Cancer Support Group Research Update - Treatment Resistance · Precision Medicine A New Drug-Pairing Strategy for Treatment-Resistant Prostate Cancer When prostate cancer changes its identity to dodge hormone therapy, one drug may not be enough. A University of Michigan team makes the case for hitting the disguise from both directions at once. Prepared for the IPCSG Newsletter  •  September 2026 Bottom Line Up Front Some advanced prostate cancers escape hormone-blocking drugs by physically changing what kind of cell they are — a process called transdifferentiation or lineage plasticity . Researchers at the University of Michigan Rogel Cancer Center report that this escape has two moving parts, and that pairing two classes of “epigenetic” drugs — a BET bromodomain inhibitor and a DNMT inhibitor — blocked both parts and slowed tumo...

Differential Radiobiological Effects of Αlpha- and Beta-Minus-Emitter Targeted Radionuclide Therapy: DNA Damage and Survival - International Journal of Radiation Oncology, Biology, Physics How to Make It Work at Lower Doses An IPCSG Newsletter feature on the radiobiology behind Pluvicto, Actinium-225, and the next wave of radioligand therapy. The author is a participant in a current Actinium 225 trial at UCSD Health Moores Cancer Center after having failed on Pluvicto. Bottom Line Up Front Targeted radionuclide therapy (TRT) — the class of treatment that includes the FDA-approved drug Pluvicto — delivers radiation directly to prostate cancer cells by riding on a molecule that locks onto PSMA , a protein studded on the surface of most prostate tumors. Two "payload" radioisotopes dominate the field: lutetium-177 (a beta-minus emitter, already approved) and actinium-225 (an alpha emitter, still investigational). A newly reported laboratory study from the German Cancer ...